在肝硬化中特利普林素的多系统血液动力学效应:一个范围审查
Jeremy Skvarce1, Albert Bui2, Peter Oro3
1Department of Internal Medicine, Community Care Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Journal of critical care
|February 16, 2025
概括
特里普林素对肝综合征与急性损伤 (HRS-AKI) 的血液动力学产生影响. 这次审查发现对心率,血压和心脏输出有不同的影响,需要进一步研究预测标记物.
科学领域:
- 心脏病学 心脏病学
- 肝病学 肝病学是一种肝病学.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 肝综合征与急性损伤 (HRS-AKI) 是晚期肝病的严重并发症.
- 目前对HRS-AKI的药理疗法有效性有限,肝移植成为主要治疗方法.
- 特里普林素作为一线HRS-AKI治疗具有前景,但其在肝硬化患者的全身血动力学效应需要彻底检查.
研究的目的:
- 在成年肝硬化患者中对特里普林素的血液动力学影响进行范围审查.
- 为了确定经常报告的血液动力学参数及其在特利普林素给药后观察到的变化.
主要方法:
- 对文献进行了全面的范围审查.
- 包括的研究涉及成年肝硬化患者,他们接受了terlipressin,并记录了血液动力学参数.
- 在主要数据库中进行了搜索,直到2024年12月,不包括非人类研究,案例报告,摘要和评论.
主要成果:
- 56项研究符合2022年获取的文章中包含的标准.
- 通常报告的参数包括心率,平均动脉压和心脏输出.
- 观察到的变化包括心率下降,平均动脉压升高,心脏输出/指数下降和全身血管阻力增加;其他结果各不相同.
结论:
- 特里普林素在各种器官系统和血管床上诱导各种血液动力学变化.
- 需要进一步的研究来确定特定的血液动力学参数是否可以预测HRS-AKI患者的特里普林素反应或不良事件.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
130
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
130
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
371
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
371
Heart Failure Drugs: Diuretics
334
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
334
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
129
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
129
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
457
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
457
Antihypertensive Drugs: Direct Renin Inhibitors
474
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
474


